Friday, July 10, 2026
🇺🇸 FDA

pharma · Obesity, Overweight · Type 2 Diabetes

Eli Lilly and

Eli Lilly Co.

Eli Lilly and clinical programs — 107 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.

Website Investor relations
Lilly Corporate Center, Indianapolis, Indiana 46285, US HQ
1876 Founded
55,860 Employees
EMA registrant Type
Company details
Status
Public
HQ
Lilly Corporate Center, Indianapolis, Indiana 46285, US
Founded
1876
Employees
55,860
Programs
107
Drugs
99
Patents
0
Official website ↗ All projects Drug pipeline News & analysis

Recent coverage

View all news & analysis →
Intelligence · Clinical Programs

Eli Lilly and projects

107 ClinicalTrials.gov programs sponsored by Eli Lilly and.

Eli Lilly and has 107 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.

All phases Phase III Phase II Phase I NDA / BLA filed Approved programs

107 programs

Clinical programs

Page 2 of 3

  1. J5E-MC-JZXB

    Eli Lilly Co.

    Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms, Neoplasm Metastasis

    phase 3 small molecule active

    1 trial

  2. J6M-MC-JSGD

    Eli Lilly Co.

    Neoplasm Metastasis, Breast Neoplasms

    phase 3 small molecule active

    1 trial

  3. METFORMIN , DAPAGLIFLOZIN

    Eli Lilly Co.

    Type 2 Diabetes

    phase 3 small molecule active

    1 trial

  4. Mirikizumab, Mirikizumab

    Eli Lilly Co.

    Ulcerative Colitis

    phase 3 small molecule active

    1 trial

  5. N1T-MC-MALO

    Eli Lilly Co.

    Metabolic Dysfunction-Associated Steatotic Liver Disease

    phase 3 small molecule active

    1 trial

  6. Orforglipron, Placebo to match LY3502970

    Eli Lilly Co.

    Obesity, Overweight

    phase 3 small molecule active

    1 trial

  7. Placebo to match LY

    Eli Lilly Co.

    Overweight or Obesity, OSA (Obstructive Sleep Apnea)

    phase 3 small molecule active

    1 trial

  8. Placebo to match LY, Muvalaplin

    Eli Lilly Co.

    Elevated Lp(a), Atherosclerotic Cardiovascular Disease (ASCVD)

    phase 3 small molecule active

    1 trial

  9. RAMUCIRUMAB, ERLOTINIB

    Eli Lilly Co.

    Metastatic Non-Small Cell Lung Cancer

    phase 3 small molecule active

    1 trial

  10. Remternetug, Placebo to match LY

    Eli Lilly Co.

    Alzheimer’s Disease

    phase 3 small molecule active

    1 trial

  11. 0.9% sodium chloride, GADOTERIC ACID

    Eli Lilly Co.

    Relapsing Multiple Sclerosis

    phase 2 small molecule active

    1 trial

  12. Eltrekibart, 0.9% sodium chloride

    Eli Lilly Co.

    Moderate to Severe Hidradenitis Suppurativa

    phase 2 small molecule active

    1 trial

  13. Flortaucipir, Placebo to match LY3372689

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  14. I3Y-MC-JPCS

    Eli Lilly Co.

    Relapsed/Refractory Solid Tumors

    phase 2 small molecule active

    1 trial

  15. I3Y-MC-JPEH

    Eli Lilly Co.

    Glioma

    phase 2 small molecule active

    1 trial

  16. I5T-MC-AACI

    Eli Lilly Co.

    Alzheimer Disease

    phase 2 small molecule active

    1 trial

  17. I7P-MC-DSAG

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  18. I8F-MC-GPIG

    Eli Lilly Co.

    Chronic Kidney Disease, CKD, Obesity, Overweight, T2D, Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  19. J1I-MC-GZBU

    Eli Lilly Co.

    Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  20. J1R-MC-GZFD

    Eli Lilly Co.

    Type 2 Diabetes

    phase 2 small molecule active

    1 trial

  21. J1S-MC-JP04

    Eli Lilly Co.

    Ewings Sarcoma

    phase 2 small molecule active

    1 trial

  22. J2R-MC-YAAD

    Eli Lilly Co.

    Nausea, Drug-Related Side Effects and Adverse Reactions, Vomiting, Neoplasms

    phase 2 small molecule active

    1 trial

  23. J2S-MC-GZMR

    Eli Lilly Co.

    Asthma

    phase 2 small molecule active

    1 trial

  24. J6E-MC-KWAN

    Eli Lilly Co.

    Ulcerative Colitis

    phase 2 small molecule active

    1 trial

  25. LOXO-RAS-20001

    Eli Lilly Co.

    KRAS G12C-Mutant Advanced Solid Tumors

    phase 2 small molecule active

    1 trial

  26. LY2875358, ERLOTINIB

    Eli Lilly Co.

    Non-Small Cell Lung Cancer

    phase 2 small molecule active

    1 trial

  27. Pirtobrutinib, Placebo tablets

    Eli Lilly Co.

    Immune Thrombocytopenia

    phase 2 small molecule active

    1 trial

  28. Placebo to match LY3540378

    Eli Lilly Co.

    Heart Failure with Preserved Ejection Fraction, Heart Failure

    phase 2 small molecule active

    1 trial

  29. Placebo to match LY3556050

    Eli Lilly Co.

    Diabetic Peripheral Neuropathy

    phase 2 small molecule active

    1 trial

  30. Placebo to match LY3848575

    Eli Lilly Co.

    Neuropathic Pain; Distal Sensory Polyneuropathy

    phase 2 small molecule active

    1 trial

  31. Verzenios 50 mg film-coated tablets, TAMOXIFEN

    Eli Lilly Co.

    Metastatic Breast Cancer

    phase 2 small molecule active

    1 trial

  32. A Phase 1 Study on the effects of LY3410738 (...

    Eli Lilly Co.

    Patients with IDH1 R132, IDH2 R140 or IDH2 R172-mutant advanced solid tumor types, including but not limited to cholangiocarcinoma, chondrosarcoma, and glioma.

    phase 1 other active

    1 trial

  33. A Study of LY3200882 in Participants With Solid Tumors.

    Eli Lilly Co.

    Metastatic cancer, Solid Tumor

    phase 1 other active

    1 trial

  34. A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors

    Eli Lilly Co.

    Metastatic Solid Tumor Advanced Solid Tumor Non-small Cell Lung Cancer SMARCA4-Deficient Tumor

    phase 1 other active

    1 trial

  35. A Study of LY4175408 in Participants With Advanced or Metastatic Solid Tumors.

    Eli Lilly Co.

    Cancer

    phase 1 other active

    1 trial

  36. A Study of LY4257496 in Participants With Cancer (OMNIRAY)

    Eli Lilly Co.

    Breast Neoplasms Colorectal Neoplasms Prostate Neoplasm Endometrial Neoplasms Neoplasm Metastasis

    phase 1 other active

    1 trial

  37. EMBER: A Study of LY3484356 in Patients with Breast or Other Non-Breast Cancers

    Eli Lilly Co.

    Breast Cancer, Endometrial cancer

    phase 1 other active

    1 trial

  38. I3Y-MC-JPCE

    Eli Lilly Co.

    Lung Cancer or Breast Cancer

    phase 1 other active

    1 trial

  39. I3Y-MC-JPEI

    Eli Lilly Co.

    Prostatic Neoplasms

    phase 1 other active

    1 trial

  40. I8H-MC-BDDG

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  41. J1I-MC-GZQF

    Eli Lilly Co.

    Type 2 Diabetes Mellitus

    phase 1 other active

    1 trial

  42. J1I-MC-GZQG

    Eli Lilly Co.

    Diabetes Mellitus

    phase 1 other active

    1 trial

  43. J2S-MC-GZML

    Eli Lilly Co.

    Healthy, Hepatic Insufficiency

    phase 1 other active

    1 trial

  44. J3L-MC-EZEH

    Eli Lilly Co.

    Normal Hepatic Function and Mild, Moderate, or Severe Hepatic Impairment

    phase 1 other active

    1 trial

  45. J3R-MC-YDAH

    Eli Lilly Co.

    Participants with Mild, Moderate, or Severe Hepatic Impairment and Participants with Normal Hepatic Function

    phase 1 other active

    1 trial

  46. J4P-MC-IYAB

    Eli Lilly Co.

    Type 1 Diabetes Mellitus

    phase 1 other active

    1 trial

  47. J5J-OX-JZZA

    Eli Lilly Co.

    KRAS G12D-mutant solid tumors.

    phase 1 other active

    1 trial

  48. J5Q-OX-JRDA

    Eli Lilly Co.

    Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Colorectal Cancer, Advanced Solid Tumor Metastatic Solid Tumor, PanKRAS.

    phase 1 other active

    1 trial

Frequently asked questions

How many clinical projects does Eli Lilly and have?

107 published programs are linked to this sponsor in our ClinicalTrials.gov index.

Is this the complete company pipeline?

This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.